Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru

January 19, 2017
Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward, Informa Pharma Intelligence’s insights global director of content, his ambitions to build a West European and US-focused specialty pharma while seeking in-country specialists to partner other markets.
Previous Video
Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates
Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized ...

Next Video
Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III
Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmye...